HRA PHARMA acquired by PERRIGO COMPANY

The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform. This structural alignment provides the organization with the scientific talent and regulatory hardware necessary to dominate high-potential European markets and accelerate the "Rx-to-OTC" pipeline globally. This maneuver allows the group to execute a definitive structural expansion of its global footprint, particularly by adding significant scale in key underpenetrated European regions where the target maintains a dominant leadership position. By incorporating the target's seasoned leadership team and its expertise in specialized categories like emergency contraception and blister care, the organization is now positioned to leverage its recognized manufacturing depth to drive deeper penetration into adjacent self-care categories.

Previously, Hra Pharma had been acquired in an LBO by Astorg / Goldman Sachs in 2016.